DFX Intelligence
Venture Capital Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Venture Capital Intelligence at $199 a month for every name. Every figure, date and source on this page is public either way.
Firms / N•••••• M••••••••• L•••
N•••••• M••••••••• L•••
N•••••• Partners is a multi-stage life sciences and healthcare venture capital firm based in Boston, MA.
venture manager, reported GAV $828M across 3 vehicles
Importance
28
moderate
Active deployment
33
moderate
Emerging
0
low
Completeness
63
high
Freshness
98
high
Research priority
14
low
Identity and regulatory footprint
- Headquarters
- Boston, MAadviserinfo.sec.gov
- Office address
- 800 BOYLSTON STREET, SUITE 2222, Boston, MA, 02199-1900adviserinfo.sec.gov
- Business phone
- 6178613831adviserinfo.sec.gov
- Website
- n••••••.partners
- SEC adviser type
- exempt reporting adviseradviserinfo.sec.gov
- SEC exemption claimed
- venture capital fund adviseradviserinfo.sec.govItem 2.B(1): advises solely venture capital funds
- Latest Form ADV
- Mar 25, 2026
- Private funds reported
- 3 (3 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $724Madviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- Owners on Schedule A
- N•••••• M••••••••• G•• L•• (General Partner), NA
- business email
- info@newpath.partnersnewpath.partnerspublished by the subject
- business phone
- 6178613831adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
2 observed deals
Stated (the firm’s website)
- Sectors
- not stated or not yet read
- Stages
- not stated or not yet read
- Geography
- boston
- Check size
- not stated; DFX does not estimate checks from round sizes
Observed (from deals on record)
Stage at participation
series a 50%series b 50%
Stage at first entry
series a 50%series b 50%
Sectors
unknown 100%
lead rate 0%follow-on rate 0%new logos, 12 months 2
Funds and vehicles
3 reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| N•••••• P••••••• I••• L• | Fund | 2023 form d first sale | Active deployment | $252M Mar 25, 2024 | 78 | $273M of $350M | Apr 22, 2024 |
| N•••••• P••••••• I•• L• | Fund | 2021 form d first sale | Mature | $382M Mar 25, 2024 | 103 | $343M of $350M | May 7, 2021 |
| N•••••• P•••••••• L••• | Fund | 2018 form d first sale | Harvest | $195M Mar 25, 2024 | 62 | $111M of $125M | Feb 22, 2019 |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
2 current, 1 departed
T••••• J••••• C•••••
Managing partnerCo-Founder And Managing Partner · since Aug 1, 2018
T••••• J••••• C•••••
Managing partnerCo-Founder And Managing Partner · since Aug 1, 2018
1 departed (kept with end dates)
- D••••• Y•••••• · Co-Founder And Chief Medical Officer · Aug 1, 2018 to Mar 30, 2022 Inference
Investments on record
2 edges, 2 companies, 0 partner-attributed
| Company | Round | Role | Partner | Round size | This investor | Date | Source |
|---|---|---|---|---|---|---|---|
| L••• T••••••••• | Series A Extension · Series A | participant | unknown | $30.0M | unknown | Aug 17, 2026 | Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) |
| C••••• M•••••••• | Series B · Series B | participant | unknown | $122M | unknown | May 14, 2026 | Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) |
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
6 relationships from shared deals, counted for the whole firm
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
5 dated events
- Mar 25, 2024N•••••• P••••••• I••• L• first reported on Form ADV by N•••••• M••••••••• L••• (Venture Capital Fund), GAV $251,600,000Fund first reported on Form ADVFundsFactN•••••• P••••••• I••• L•SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2022N•••••• P••••••• I•• L• first reported on Form ADV by N•••••• M••••••••• L••• (Venture Capital Fund), GAV $43,624,443Fund first reported on Form ADVFundsFactN•••••• P••••••• I•• L•SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2022D••••• Y•••••• (Co-Founder And Chief Medical Officer) no longer on Schedule A of N•••••• M••••••••• L•••
- Dec 21, 2018N•••••• M••••••••• L••• first filed Form ADV (ERA, venture capital fund adviser exemption)First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Dec 21, 2018N•••••• P•••••••• L••• first reported on Form ADV by N•••••• M••••••••• L••• (Venture Capital Fund), GAV $100,000,000Fund first reported on Form ADVFundsFactN•••••• P•••••••• L•••SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Classification history
- Sep 12, 2026Institutional venture firm (confirmed, 95%, cls-1)venture manager, reported GAV $828M across 3 vehicles
Evidence
42 observations from 4 sources